Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 483

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Open access
Barbhaiya, Medha, Zuily, Stephane, Naden, Ray, Hendry, Alison, Manneville, Florian, Amigo, Mary‐Carmen, Amoura, Zahir, Andrade, Danieli, Andreoli, Laura, Artim‐Esen, Bahar, Atsumi, Tatsuya, Avcin, Tadej, Belmont, H. Michael, Bertolaccini, Maria Laura, Branch, D. Ware, Carvalheiras, Graziela, Casini, Alessandro, Cervera, Ricard, Cohen, Hannah, Costedoat‐Chalumeau, Nathalie, Crowther, Mark, de Jesus, Guilherme, Delluc, Aurelien, Desai, Sheetal, De Sancho, Maria, Devreese, Katrien M., Diz‐Kucukkaya, Reyhan, Duarte‐Garcia, Ali, Frances, Camille, Garcia, David, Gris, Jean‐Christophe, Jordan, Natasha, Leaf, Rebecca K., Kello, Nina, Knight, Jason S., Laskin, Carl, Lee, Alfred I., Legault, Kimberly, Levine, Steve R., Levy, Roger A., Limper, Maarten, Lockshin, Michael D., Mayer‐Pickel, Karoline, Musial, Jack, Meroni, Pier Luigi, Orsolini, Giovanni, Ortel, Thomas L., Pengo, Vittorio, Petri, Michelle, Pons‐Estel, Guillermo, Gomez‐Puerta, Jose A., Raimboug, Quentin, Roubey, Robert, Sanna, Giovanni, Seshan, Surya V., Sciascia, Savino, Tektonidou, Maria G., Tincani, Angela, Wahl, Denis, Willis, Rohan, Yelnik, Cecile, Zuily, Catherine, Guillemin, Francis, Costenbader, Karen, Erkan, Doruk, the ACR/EULAR APS Classification Criteria Collaborators · 2023 · Arthritis & Rheumatology

Abstract

Objective: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods: This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real‐world patient scenarios, and weighting via consensus‐based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results: The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL‐associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid‐phase enzyme‐linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β 2‐glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versu s 86%, and a sensitivity of 84% versus 99%. Conclusion: These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk‐stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.42624

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 483

Metadata

Authors
Barbhaiya, M., Zuily, S., Naden, R., Hendry, A., Manneville, F., Amigo, M., Amoura, Z., Andrade, D., Andreoli, L., Artim‐Esen, B., Atsumi, T., Avcin, T., Belmont, H. M., Bertolaccini, M. L., Branch, D. W., Carvalheiras, G., Casini, A., Cervera, R., Cohen, H., Costedoat‐Chalumeau, N., Crowther, M., de Jesus, G., Delluc, A., Desai, S., De Sancho, M., Devreese, K. M., Diz‐Kucukkaya, R., Duarte‐Garcia, A., Frances, C., Garcia, D., Gris, J., Jordan, N., Leaf, R. K., Kello, N., Knight, J. S., Laskin, C., Lee, A. I., Legault, K., Levine, S. R., Levy, R. A., Limper, M., Lockshin, M. D., Mayer‐Pickel, K., Musial, J., Meroni, P. L., Orsolini, G., Ortel, T. L., Pengo, V., Petri, M., Pons‐Estel, G., Gomez‐Puerta, J. A., Raimboug, Q., Roubey, R., Sanna, G., Seshan, S. V., Sciascia, S., Tektonidou, M. G., Tincani, A., Wahl, D., Willis, R., Yelnik, C., Zuily, C., Guillemin, F., Costenbader, K., Erkan, D., & Collaborators, T. A. A. C. C.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2023-08-28
Volume
75
Issue
10
Pages
1687-1702
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W4386209525
Cited by
483
References
42
FWCI
83.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.